Lundbeck appoints senior vice president for business development
Ole Vahlgren has been the driving force in business development at Lundbeck for 10 years
As a driving force in business development for nearly 10 years, Vahlgren has played a significant role in Lundbeck's successful development. He is responsible for supporting and supplementing Lundbeck's own drug research and development through corporate partnerships and acquisition of companies and products.
‘Ole is key to our business development, ensuring that we benefit from business opportunities both inside and outside the company. He is the person who develops and strengthens existing partnerships, and he is also the one who explores new market opportunities such as acquisitions and in-licensing of new drugs,’ said Lundbeck ceo Ulf Wiinberg.
During his time at Lundbeck, Vahlgren has held a number of positions in strategy and business development. He has also been managing director of Gramineer, the Swedish biotech company. He holds a degree in Civil Engineering as well as an MBA.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Drug approvals: more numerous but niche
After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
